{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:55:50Z","timestamp":1791816950491,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40262-024-01435-7","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T12:02:00Z","timestamp":1730980920000},"page":"1631-1648","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian"],"prefix":"10.1007","volume":"63","author":[{"given":"Christine","family":"Brase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atef","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1346-9336","authenticated-orcid":false,"given":"Friederike","family":"Kanefendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"1435_CR1","unstructured":"European Medicines Agency. ICH: E 7: Studies in support of special populations: Geriatrics - Step 5. 2010. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-7-studies-support-special-populations-geriatrics-step-5_en.pdf. Accessed Feb 22, 2024"},{"issue":"17","key":"1435_CR2","doi-asserted-by":"publisher","first-page":"12203","DOI":"10.1021\/acs.jmedchem.3c00795","volume":"66","author":"S Roehrig","year":"2023","unstructured":"Roehrig S, Ackerstaff J, Jim\u00e9nez N\u00fa\u00f1ez E, et al. Design and preclinical characterization program toward asundexian (BAY 2433334), an oral Factor XIa inhibitor for the prevention and treatment of thromboembolic disorders. J Med Chem. 2023;66(17):12203\u201324. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00795.","journal-title":"J Med Chem"},{"issue":"10","key":"1435_CR3","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1111\/jth.15439","volume":"19","author":"D Thomas","year":"2021","unstructured":"Thomas D, Kanefendt F, Schwers S, Unger S, Yassen A, Boxnick S. First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa. J Thromb Haemost. 2021;19(10):2407\u201316. https:\/\/doi.org\/10.1111\/jth.15439.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"1435_CR4","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1111\/bcp.15230","volume":"88","author":"D Kubitza","year":"2022","unstructured":"Kubitza D, Heckmann M, Distler J, Koechel A, Schwers S, Kanefendt F. Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: a randomized phase 1 multiple-dose study. Br J Clin Pharmacol. 2022;88(7):3447\u201362. https:\/\/doi.org\/10.1111\/bcp.15230.","journal-title":"Br J Clin Pharmacol"},{"key":"1435_CR5","unstructured":"ClinicalTrials.gov. A study to test asundexian to prevent a clot-related stroke in participants after an acute ischemic stroke or high-risk TIA\/mini-stroke (transient ischemic attack) (OCEANIC-STROKE). 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05686070. Accessed Oct 23, 2023."},{"issue":"8","key":"1435_CR6","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/cir.0000000000001123","volume":"147","author":"CW Tsao","year":"2023","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93-621. https:\/\/doi.org\/10.1161\/cir.0000000000001123.","journal-title":"Circulation"},{"issue":"8","key":"1435_CR7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.hpb.2016.05.011","volume":"18","author":"KP Cieslak","year":"2016","unstructured":"Cieslak KP, Baur O, Verheij J, Bennink RJ, van Gulik TM. Liver function declines with increased age. HPB (Oxford). 2016;18(8):691\u20136. https:\/\/doi.org\/10.1016\/j.hpb.2016.05.011.","journal-title":"HPB (Oxford)"},{"key":"1435_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2020.101151","volume":"63","author":"Y Fang","year":"2020","unstructured":"Fang Y, Gong AY, Haller ST, Dworkin LD, Liu Z, Gong R. The ageing kidney: molecular mechanisms and clinical implications. Ageing Res Rev. 2020;63: 101151. https:\/\/doi.org\/10.1016\/j.arr.2020.101151.","journal-title":"Ageing Res Rev"},{"issue":"15","key":"1435_CR9","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.118.008703","volume":"7","author":"WA Huang","year":"2018","unstructured":"Huang WA, Dunipace EA, Sorg JM, Vaseghi M. Liver disease as a predictor of new-onset atrial fibrillation. J Am Heart Assoc. 2018;7(15): e008703. https:\/\/doi.org\/10.1161\/jaha.118.008703.","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"1435_CR10","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1161\/strokeaha.120.029680","volume":"52","author":"DM Kelly","year":"2021","unstructured":"Kelly DM, Ademi Z, Doehner W, et al. Chronic kidney disease and cerebrovascular disease: consensus and guidance from a KDIGO controversies conference. Stroke. 2021;52(7):e328\u201346. https:\/\/doi.org\/10.1161\/strokeaha.120.029680.","journal-title":"Stroke"},{"issue":"8","key":"1435_CR11","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.122.028496","volume":"12","author":"SM Kim","year":"2023","unstructured":"Kim SM, Jeong Y, Kim YL, et al. Association of chronic kidney disease with atrial fibrillation in the general adult population: a nationwide population-based study. J Am Heart Assoc. 2023;12(8): e028496. https:\/\/doi.org\/10.1161\/jaha.122.028496.","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"1435_CR12","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1111\/liv.13459","volume":"37","author":"H Lee","year":"2017","unstructured":"Lee H, Choi EK, Rhee TM, et al. Cirrhosis is a risk factor for atrial fibrillation: a nationwide, population-based study. Liver Int. 2017;37(11):1660\u20137. https:\/\/doi.org\/10.1111\/liv.13459.","journal-title":"Liver Int"},{"issue":"10333","key":"1435_CR13","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/s0140-6736(22)00456-1","volume":"399","author":"JP Piccini","year":"2022","unstructured":"Piccini JP, Caso V, Connolly SJ, et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet. 2022;399(10333):1383\u201390. https:\/\/doi.org\/10.1016\/s0140-6736(22)00456-1.","journal-title":"Lancet"},{"issue":"10357","key":"1435_CR14","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/s0140-6736(22)01588-4","volume":"400","author":"A Shoamanesh","year":"2022","unstructured":"Shoamanesh A, Mundl H, Smith EE, et al. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2022;400(10357):997\u20131007. https:\/\/doi.org\/10.1016\/s0140-6736(22)01588-4.","journal-title":"Lancet"},{"issue":"16","key":"1435_CR15","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1161\/circulationaha.122.061612","volume":"146","author":"SV Rao","year":"2022","unstructured":"Rao SV, Kirsch B, Bhatt DL, et al. A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral Factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation. 2022;146(16):1196\u2013206. https:\/\/doi.org\/10.1161\/circulationaha.122.061612.","journal-title":"Circulation"},{"issue":"4","key":"1435_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s13318-023-00838-4","volume":"48","author":"I Piel","year":"2023","unstructured":"Piel I, Engelen A, Lang D, et al. Metabolism and disposition of the novel oral Factor XIa inhibitor asundexian in rats and in humans. Eur J Drug Metab Pharmacokinet. 2023;48(4):411\u201325. https:\/\/doi.org\/10.1007\/s13318-023-00838-4.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1435_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15981","author":"F Kanefendt","year":"2023","unstructured":"Kanefendt F, Brase C, Jungmann N, Fricke R, Engelen A, Schmitz S. Pharmacokinetics of asundexian with combined CYP3A and P-gp inhibitors and an inducer: target in vitro and in vivo studies. Br J Clin Pharmacol. 2023. https:\/\/doi.org\/10.1111\/bcp.15981.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1435_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/cpdd.1207","volume":"12","author":"F Kanefendt","year":"2023","unstructured":"Kanefendt F, Brase C, Unger S, Kubitza D. Effects of tablet formulation, food, or gastric pH on the bioavailability of asundexian. Clin Pharmacol Drug Dev. 2023;12(2):219\u201330. https:\/\/doi.org\/10.1002\/cpdd.1207.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"4","key":"1435_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4155\/bio-2022-0107","volume":"15","author":"L Fiebig","year":"2023","unstructured":"Fiebig L, Helmes S, Kaiser M, Werner D. Determination of asundexian and its metabolite M-10 in human plasma by LC-MS\/MS. Bioanalysis. 2023;15(4):197\u2013206. https:\/\/doi.org\/10.4155\/bio-2022-0107.","journal-title":"Bioanalysis"},{"issue":"6","key":"1435_CR20","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/jth.15700","volume":"20","author":"S Heitmeier","year":"2022","unstructured":"Heitmeier S, Visser M, Tersteegen A, et al. Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa. J Thromb Haemost. 2022;20(6):1400\u201311. https:\/\/doi.org\/10.1111\/jth.15700.","journal-title":"J Thromb Haemost"},{"key":"1435_CR21","unstructured":"European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-pharmacokinetics-medicinal-products-patients-decreased-renal-function_en.pdf. Accessed Oct 23, 2023."},{"key":"1435_CR22","unstructured":"US Food & Drug Administration. Pharmacokinetics in patients with impaired hepatic function: Study design, data analysis, and impact on dosing and labeling. 2003. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/pharmacokinetics-patients-impaired-hepatic-function-study-design-data-analysis-and-impact-dosing-and. Accessed Oct 23, 2023."},{"issue":"6","key":"1435_CR23","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40262-014-0146-1","volume":"53","author":"L Lalande","year":"2014","unstructured":"Lalande L, Charpiat B, Leboucher G, Tod M. Consequences of renal failure on non-renal clearance of drugs. Clin Pharmacokinet. 2014;53(6):521\u201332. https:\/\/doi.org\/10.1007\/s40262-014-0146-1.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1435_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1067\/mcp.2002.121829","volume":"71","author":"LZ Benet","year":"2002","unstructured":"Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71(3):115\u201321. https:\/\/doi.org\/10.1067\/mcp.2002.121829.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1435_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/sdi.12374","volume":"28","author":"TD Nolin","year":"2015","unstructured":"Nolin TD. A synopsis of clinical pharmacokinetic alterations in advanced CKD. Semin Dial. 2015;28(4):325\u20139. https:\/\/doi.org\/10.1111\/sdi.12374.","journal-title":"Semin Dial"},{"issue":"1 Suppl","key":"1435_CR26","doi-asserted-by":"publisher","first-page":"10s","DOI":"10.1177\/0091270011413588","volume":"52","author":"J Naud","year":"2012","unstructured":"Naud J, Nolin TD, Leblond FA, Pichette V. Current understanding of drug disposition in kidney disease. J Clin Pharmacol. 2012;52(1 Suppl):10s\u201322s. https:\/\/doi.org\/10.1177\/0091270011413588.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"1435_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13895","volume":"17","author":"H Chen","year":"2024","unstructured":"Chen H, Hashizume K, Kanefendt F, Brase C, Schmitz S, Liu T. Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data. Clin Transl Sci. 2024;17(8): e13895. https:\/\/doi.org\/10.1111\/cts.13895.","journal-title":"Clin Transl Sci"},{"key":"1435_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/978-1-4939-2074-7_23","volume":"1250","author":"S Heinz","year":"2015","unstructured":"Heinz S, Braspenning J. Measurement of blood coagulation factor synthesis in cultures of human hepatocytes. Methods Mol Biol. 2015;1250:309\u201316. https:\/\/doi.org\/10.1007\/978-1-4939-2074-7_23.","journal-title":"Methods Mol Biol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01435-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01435-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01435-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T11:07:18Z","timestamp":1731928038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01435-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1435"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01435-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"29 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by Bayer AG, Wuppertal, Germany. Editorial support, including writing, fact checking, referencing, figure preparation, formatting, proofreading and submission was provided by Moamen Hammad, PhD, Patricia Badia Folgado, MSc and Melissa Ward, BA, all of Scion (a division of Prime, London, UK) supported by Bayer AG, Wuppertal, Germany according to Good Publication Practice guidelines (<u>Link<\/u>).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Christine Brase and Friederike Kanefendt are employees of Bayer AG and own shares or share options in the company. Sebastian Schmitz was an employee of Bayer AG at the time of the manuscript development and may own shares or share options in the company. Katharina Sommer is an employee of ClinStat GmbH and reports consulting or advisory roles of her CRO with Bayer AG. Atef Halabi has nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The conduct of the clinical studies met all local legal and regulatory requirements. The studies were conducted in accordance with the Declaration of Helsinki and the International Council for Harmonisation guideline E6: Good Clinical Practice. The protocols and other related materials were reviewed and approved by the relevant institutional boards for each study: IntegReview Institutional Review Board, Austin, Texas and QPS Bio-Kinetic, Biokinetic Clinical Applications institutional review board, Springfield, Missouri for study 1 and Ethik-Kommission der Arztekammer Schleswig-Holstein, Kiel, Germany for studies 2 and 3.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the studies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Availability of the data underlying this publication will be determined later according to Bayer\u2019s commitment to the EFPIA\/PhRMA principles for responsible clinical trial data sharing. This pertains to scope, time point, and process of data access. As such, Bayer commits to sharing, upon request from qualified scientific and medical researchers, participant-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in participants for medicines and indications approved in the United States (US) and European Union (EU) as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 1, 2014. Interested researchers can use\n                      \n                      to request access to anonymised participant-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care. Information on the Bayer criteria for listing studies and other relevant information is provided in the study sponsor\u2019s section of the portal. Data access will be granted to anonymised participant-level data, protocols, and clinical study reports after approval by an independent scientific review panel. Bayer is not involved in the decisions made by the independent review panel. Bayer will take all necessary measures to ensure that participant privacy is safeguarded.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Christine Brase and  Friederike Kanefendt (all studies) and Sebastian Schmitz (studies 1 and 2) and Katharina Sommer (study 3) made substantial contributions to the conception or design of the work. Christine Brase and Friederike Kanefendt (all studies), and Sebastian Schmitz (studies 1 and 2), Katharina Sommer (study 3) and Atef Halabi (studies 2 and 3) made substantial contributions to the acquisition of the data. Christine Brase and Friederike Kanefendt (all studies) and Sebastian Schmitz (studies 1 and 2) and Katharina Sommer (study 3) made substantial contributions to the analysis of the data. Christine Brase and Friederike Kanefendt (all studies) and Sebastian Schmitz (studies 1 and 2) and Katharina Sommer (study 3) made substantial contributions to the interpretation of the results. All authors drafted the work or revised it critically for important intellectual content, approved the version to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}